These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 12827536)

  • 41. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant.
    Alexander BD; Perfect JR; Daly JS; Restrepo A; Tobón AM; Patino H; Hardalo CJ; Graybill JR
    Transplantation; 2008 Sep; 86(6):791-6. PubMed ID: 18813103
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
    Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B;
    N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Voriconazole.
    Jeu L; Piacenti FJ; Lyakhovetskiy AG; Fung HB
    Clin Ther; 2003 May; 25(5):1321-81. PubMed ID: 12867215
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole.
    Espinel-Ingroff A; Fothergill A; Ghannoum M; Manavathu E; Ostrosky-Zeichner L; Pfaller M; Rinaldi M; Schell W; Walsh T
    J Clin Microbiol; 2005 Oct; 43(10):5243-6. PubMed ID: 16207990
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Breakthrough Scedosporium prolificans infection while receiving voriconazole prophylaxis in an allogeneic stem cell transplant recipient.
    Tong SY; Peleg AY; Yoong J; Handke R; Szer J; Slavin M
    Transpl Infect Dis; 2007 Sep; 9(3):241-3. PubMed ID: 17605752
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacoeconomics of voriconazole in the management of invasive fungal infections.
    Al-Badriyeh D; Heng SC; Neoh CF; Slavin M; Stewart K; Kong DC
    Expert Rev Pharmacoecon Outcomes Res; 2010 Dec; 10(6):623-36. PubMed ID: 21155694
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mold infections in lung transplant recipients.
    Bhaskaran A; Hosseini-Moghaddam SM; Rotstein C; Husain S
    Semin Respir Crit Care Med; 2013 Jun; 34(3):371-9. PubMed ID: 23821511
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses.
    Öz Y; Özdemir HG; Gökbolat E; Kiraz N; Ilkit M; Seyedmousavi S
    Mycopathologia; 2016 Apr; 181(3-4):225-33. PubMed ID: 26612621
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [In vitro antifungal activity of voriconazole: New data after the first years of clinical experience].
    Quindós G; Carrillo-Muñoz AJ; Eraso E; Cantón E; Pemán J
    Rev Iberoam Micol; 2007 Sep; 24(3):198-208. PubMed ID: 17874856
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
    Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Identification of filamentous fungi isolated from clinical samples by two different methods and their susceptibility results].
    Direkel S; Otağ F; Aslan G; Ulger M; Emekdaş G
    Mikrobiyol Bul; 2012 Jan; 46(1):65-78. PubMed ID: 22399173
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changing epidemiology of rare mould infections: implications for therapy.
    Malani AN; Kauffman CA
    Drugs; 2007; 67(13):1803-12. PubMed ID: 17722951
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Voriconazole: a new triazole antifungal agent.
    Pearson MM; Rogers PD; Cleary JD; Chapman SW
    Ann Pharmacother; 2003 Mar; 37(3):420-32. PubMed ID: 12639175
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Voriconazole for serious fungal infections.
    Gothard P; Rogers TR
    Int J Clin Pract; 2004 Jan; 58(1):74-80. PubMed ID: 14994974
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mold Infections in Solid Organ Transplant Recipients.
    Lemonovich TL
    Infect Dis Clin North Am; 2018 Sep; 32(3):687-701. PubMed ID: 30146030
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Successful treatment with voriconazole of Aspergillus brain abscess in a boy with medulloblastoma.
    Stiefel M; Reiss T; Staege MS; Rengelshausen J; Burhenne J; Wawer A; Foell JL
    Pediatr Blood Cancer; 2007 Aug; 49(2):203-7. PubMed ID: 16333861
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients.
    Troke P; Aguirrebengoa K; Arteaga C; Ellis D; Heath CH; Lutsar I; Rovira M; Nguyen Q; Slavin M; Chen SC;
    Antimicrob Agents Chemother; 2008 May; 52(5):1743-50. PubMed ID: 18212110
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro testing of Aspergillus fumigatus clinical isolates for susceptibility to voriconazole, amphotericin B and itraconazole: comparison of sensititre versus NCCLS M38-A using two different inocula.
    Drago M; Scaltrito MM; Cariani L; Morace G
    J Chemother; 2004 Oct; 16(5):474-8. PubMed ID: 15565915
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Susceptibility of filamentous fungi to voriconazole tested by two microdilution methods.
    Linares MJ; Charriel G; Solís F; Rodriguez F; Ibarra A; Casal M
    J Clin Microbiol; 2005 Jan; 43(1):250-3. PubMed ID: 15634979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.